Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

This study has been terminated.
(The enrollment rate at most centers was unlikely to result in the recruitment of the planned sample size of 40 evaluable subjects.)
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00845338
First received: February 16, 2009
Last updated: November 20, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2007
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)